Why Are These Stocks Making Huge Moves Before the Bell Today? Top Pre-Market Movers for July 28

Tuesday, July 28, 2026. The pre-market is active before the bell rings. Nvidia is up 4.2% to $127.48 on 12.3M shares (3.1x the 30-day pre-market average of 3.9M). Eli Lilly is down 3.8% to $892.14 on an FDA regulatory setback. Broadcom is ripping 5.1% to $198.76 on beat earnings. Tesla is down 2.3% to $271.09 on delivery miss guidance. And Solvent Recovery Systems just gapped up 18.7% to $4.82 on acquisition news. Here's why these stocks are moving this morning — and what to watch when the opening bell rings.

What's Driving These Stock Moves Today

Nvidia: AI Infrastructure Demand Accelerating

Nvidia is up 4.2% in pre-market trading to $127.48 after Bloomberg reported that major cloud providers (AWS, Microsoft Azure, Google Cloud) accelerated GPU purchase orders for Q3. The orders total $4.2B, marking the highest quarterly aggregate since Q4 2025. This confirms that enterprise AI workloads are not slowing — they're accelerating. Historically, Nvidia pre-market gaps like this tend to hold at the open if volume supports it. Today's 12.3M pre-market shares are already 3.1x average, signaling institutional buying.

This move also suggests that concerns about AI spending moderation — which pressured the stock in June — were overblown. The stock is now retesting its June 15 high of $128.32.

Eli Lilly: FDA Regulatory Delay Stings

Eli Lilly is down 3.8% to $892.14 after the FDA requested additional clinical data for LY3724472, its once-daily obesity treatment candidate. The decision has been pushed from Q3 2026 (expected in September) to Q4 2026 (likely November/December). This is a delay, not a rejection, but the market is pricing it as a setback because first-mover advantage in the obesity drug space is worth billions. Novo Nordisk's Ozempic and Zepbound already dominate. A 3-month delay for Eli Lilly means Novo extends its window unopposed.

The FDA cited insufficient pharmacokinetic data in the geriatric population. This is a technical, not efficacy-based, concern — suggesting approval is likely when data comes in. But the delay costs Eli Lilly an estimated $150M in Q3-Q4 revenue it had modeled.

Broadcom: Earnings Beat + Guidance Raise

Broadcom is up 5.1% to $198.76 pre-market on strong Q3 earnings released after yesterday's close. The semiconductor giant reported EPS of $8.47 versus the $8.12 consensus, and revenue of $13.2B versus $13.0B expected. More management raised full-year 2026 guidance to $32.8B revenue (from $32.1B prior), signaling that the AI infrastructure buildout is sustaining demand across networking chips, storage controllers, and infrastructure software.

The guidance raise is the real catalyst. It suggests Broadcom sees no demand cliff in H2 2026. Compare this to Intel's guidance miss last week, which spooked the semiconductor sector. Broadcom is the counternarrative: some semis are thriving.

Tesla: Delivery Miss Guidance Cut

Tesla is down 2.3% to $271.09 pre-market after management issued guidance that Q3 2026 deliveries will be 405K units, below the 420K consensus and marking a sequential decline from Q2's 445K. Management cited production slowdowns at the Berlin Gigafactory due to parts supply constraints. This is the first negative delivery guidance from Tesla in four quarters, and the market is repricing accordingly.

The move is modest (down 2.3%) because the shortfall was partially priced in after recent supply chain reports. But it signals that Tesla's production ramp is hitting real headwinds, not just cycle noise.

Solvent Recovery Systems (SRS): Acquisition Announced

Solvent Recovery Systems, a microcap industrial systems company, is gapping up 18.7% to $4.82 pre-market on announcement that it has been acquired by Evoqua Water Technologies for $5.15 per share in an all-cash deal. The deal values SRS at approximately $380M including debt. For SRS shareholders, the 6.8% premium above yesterday's close provides immediate arbitrage value. The pre-market gap reflects the spread between the announced price ($5.15) and Evoqua's typical close-to-announcement premium expectations.

This is a straight M&A play — low volatility, high certainty. Expect SRS to trade in a tight range between $5.00-$5.15 until deal close (expected Q4 2026).

Key Levels to Watch at the Open

Nvidia (NVDA)

Pre-market high: $127.92 | 50-day MA: $124.18 | 200-day MA: $119.47 | 52-week high: $134.56 (June 18) | 52-week low: $98.22 (January 31). If Nvidia holds above $126 at the open on volume >30M shares, expect a retest of $128.32 (June high). Support sits at $125.10 (yesterday's close).

Eli Lilly (LLY)

Pre-market low: $889.22 | 50-day MA: $906.34 | 200-day MA: $881.45 | 52-week high: $968.15 (May 2026) | 52-week low: $814.90 (February 2026). The stock is breaking below its 50-day MA, which is the first technical warning. Support is at $885 (yesterday's gap-down open close). A break below $880 opens the door to $860.

Broadcom (AVGO)

Pre-market high: $199.14 | 50-day MA: $192.76 | 200-day MA: $176.34 | 52-week high: $205.60 (June 2026) | 52-week low: $154.12 (March 2026). Broadcom is moving above its 50-day MA decisively. Resistance sits at $201 (technical level from June). Volume is tracking 22.1M shares pre-market (2.8x average), confirming institutional interest.

Tesla (TSLA)

Pre-market low: $269.88 | 50-day MA: $287.34 | 200-day MA: $296.12 | 52-week high: $312.18 (April 2026) | 52-week low: $142.04 (October 2025). Tesla is now below its 50-day and 200-day MAs — a bearish technical setup. Support sits at $268 (technical level from July 15). A break below $265 targets $250.

Solvent Recovery Systems (SRS)

Deal price: $5.15 | Yesterday's close: $4.82 | Pre-market: $4.82 (up 18.7%). Arbitrage spread is tight at $0.33 ($5.15 deal price minus $4.82). Merger risk is low given the all-cash structure and established buyer (Evoqua), so SRS should trade near deal price through close.

What Analysts Say About These Stocks

Nvidia: 18 Buy, 5 Hold, 1 Sell. Average price target: $148.27 (16.3% upside from pre-market). Consensus: Strong buy on AI secular trend. Morgan Stanley ($165 target) initiated overweight on data center tailwinds; JPMorgan ($152 target) sees 2027 upside as China demand stabilizes post-tariff uncertainty.

Eli Lilly: 16 Buy, 8 Hold, 0 Sell. Average price target: $945.14 (5.9% upside from pre-market). The 3-month delay is a temporary setback; analysts expect LY3724472 approval in Q4 2026 with 2027 peak sales of $3.2B. The valuation remains intact on this dip.

Broadcom: 17 Buy, 4 Hold, 0 Sell. Average price target: $215.32 (8.3% upside from pre-market). Consensus: Guidance raise validates AI infrastructure thesis. UBS ($225 target) raised estimates on networking strength; Citigroup ($220 target) sees 2027 margins expanding as software mix grows.

Tesla: 12 Buy, 9 Hold, 4 Sell. Average price target: $289.45 (6.8% upside from pre-market, though note the wide range of outcomes). Bulls see Q3 deliveries as a temporary blip; bears cite structural margin pressure in EVs. The consensus is becoming more constructive as EV competition intensifies and Tesla's price cuts stick.

What's Next for These Stocks

Nvidia: Next catalyst is Q2 FY2027 earnings on August 28. Expectations: EPS guidance of $0.68 on $30.1B revenue. If confirmed, this validates the AI data center story. Watch for commentary on AI model cost optimization (a headwind) versus new model launches (a tailwind).

Eli Lilly: FDA decision on LY3724472 in Q4 2026 (likely November). Bull case: Approval in Q4 clears a major catalyst; obesity market reaches $100B by 2030, and Eli Lilly takes 20%+ share. Bear case: FDA requests more data beyond Q4, pushing approval to 2027; Novo Nordisk deepens moat.

Broadcom: Q4 2026 earnings in late January 2027. The company will report full 2026 results and guide 2027. Watch for AI infrastructure spending trends in Q1 2027 — if customers defer orders, Broadcom's stock faces pressure. Bull case: AI capex accelerates; 2027 revenue reaches $35B.

Tesla: Q3 2026 earnings on October 23. Delivery count for Q3 (405K guidance) will be the headline. If Tesla hits 405K, the stock stabilizes; if it misses again, bears target $250. Next catalysts also include new product announcements (Roadster refresh rumored for Q4) and margin commentary on price wars in China.

Solvent Recovery Systems: Merger close expected Q4 2026. Monitor for deal risk (antitrust, financing, MAC clause) — unlikely given Evoqua's scale, but regulatory filings are due by mid-August.

Frequently Asked Questions

Why are these stocks moving so much pre-market today?

Earnings beats (Broadcom), FDA regulatory delays (Eli Lilly), guidance cuts (Tesla), corporate demand confirmations (Nvidia), and M&A announcements (SRS) are driving individual moves. When multiple catalysts hit at once, the pre-market becomes volatile as institutional traders position before the open. Volume tends to be 2-4x normal pre-market volume, amplifying price moves.

Should I trade on pre-market moves or wait for the open?

Pre-market liquidity is thin and bid-ask spreads are wide — on average 2-3x wider than regular market hours. Institutions use the pre-market to position, not to execute large orders. Most retail traders should wait for the open when spreads tighten and volume surges. The first 30 minutes of regular hours typically reprices the pre-market moves fairly.

Which of these stocks is the best buy today?

Analyst consensus favors Broadcom (guidance raise on AI infrastructure) and Nvidia (enterprise demand accelerating). Eli Lilly is a contrarian play: the FDA delay stings, but 2027 upside remains intact if approval comes as expected. We do not provide investment advice — consult your financial advisor or see our stock evaluation guide to build your own thesis.

Will these pre-market moves hold at the open?

Historical data shows that 65-70% of pre-market gaps hold their direction at the regular market open, though magnitude often compresses. Nvidia's 4.2% gap will likely compress to 2-3% at the open unless new news drops. Tesla's 2.3% gap may reverse partially on short covering. Broadcom's 5.1% gap is backed by earnings, so it's more likely to stick. SRS's deal-driven gap is structural and will hold.

Where should I monitor real-time updates?

Check our Nvidia stock page, Eli Lilly stock page, and Broadcom stock page for live price updates, charts, and analyst commentary throughout the day. For more context on how to read these price moves, see our guide to understanding volume.

The Bottom Line

Pre-market movers on July 28 tell a story: AI infrastructure demand is real and accelerating (Nvidia), semis that can grow are outperforming (Broadcom), but regulatory uncertainty and execution concerns remain (Eli Lilly and Tesla). The Solvent Recovery Systems deal is a routine M&A arbitrage play. At the open, watch for the first 30 minutes to confirm or reverse these pre-market moves. Volume will be the key — if it sustains 30M+ shares for Nvidia and Broadcom, the rallies hold. For Eli Lilly and Tesla, monitor whether the declines accelerate or bounce back as traders reassess. The earnings season is in full swing, and surprises are pricing in faster than usual. Stay on market news for updates throughout the day.